Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.61 |
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 7/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13420010 | 0.87 | CYP2A6 (0.47) | APPESR1ESR2CYP2E1CYP3A4 | |
| SCHEMBL2767502 | 0.85 | CYP2E1 (0.45) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL5349623 | 0.85 | CYP2E1 (0.45) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL4452318 | 0.85 | APP (0.57) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL10332066 | 0.82 | CYP2E1 (0.42) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL6657730 | 0.80 | APP (0.52) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL13026609 | 0.80 | IKBKB (0.44) | APPESR1ESR2CYP2E1CYP3A4 | |
| SCHEMBL10084289 | 0.79 | CYP2A6 (0.64) | HSD17B1HSD17B2TRPV1CYP2E1CYP3A4 | |
| SCHEMBL8984275 | 0.79 | ESR1 (0.51) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL13197660 | 0.78 | CYP3A4 (0.40) | APPESR1ESR2HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101068803-A | Biaryloxymethylarene carboxylic acid compounds | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | APP 1359/4885ESR1 1085/4885ESR2 232/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | APP 1359/4885ESR1 1085/4885ESR2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.